Showing results (71-80 of 92) with videos related to

Sort By:
Pageof 10
Cancers|August 10, 2024
Analysis of Molecular Imaging and Laboratory Baseline Biomarkers in PSMA-RLT: Whole-Body Total Lesion PSMA (TLP) Predicts Overall SurvivalConnor Hein, Caroline Burgard, Arne Blickle, et al.
The American Journal of Case Reports|December 8, 2023
Unusual Case of Splenic Metastasis in Adenosquamous Carcinoma of the Cervix Uteri: Diagnosis and Treatment ConsiderationsGilbert Georg Klamminger, Caroline Burgard, Florian Rosar, et al.
Current Oncology (Toronto, Ont.)|June 25, 2026
Automated PROMISE V2 Scoring from PSMA PET/CT Reports Using Large Language Models: A Comparative Evaluation of Prompt Design and Model PerformanceTilman Speicher, Isa Ethem Demirkol, Arne Blickle, et al.
EJNMMI Research|July 6, 2025
Tolerability of PSMA radioligand therapy in metastatic prostate cancer patients with baseline mild to moderate leukopeniaMoritz B Bastian, Tilman Speicher, Arne Blickle, et al.
Clinical Nuclear Medicine|May 13, 2025
PSMA Radioligand Therapy in Advanced Age: Insights From an 85y+ mCRPC Patient CohortMoritz B Bastian, Benedikt Wörl, Arne Blickle, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|October 7, 2024
Outstanding increase in tumor-to-background ratio over time allows tumor localization by [89Zr]Zr-PSMA-617 PET/CT in early biochemical recurrence of prostate cancerCaroline Burgard, Florian Rosar, Elena Larsen, et al.
Clinical Nuclear Medicine|November 27, 2024
Outcome and Renal Safety of PSMA-Targeted Radioligand Therapy in mCRPC Patients With Preexisting Impaired Renal FunctionMoritz B Bastian, Maike Sieben, Caroline Burgard, et al.
Cancers|February 13, 2020
PSA and PSA Kinetics Thresholds for the Presence of 68Ga-PSMA-11 PET/CT-Detectable Lesions in Patients With Biochemical Recurrent Prostate CancerManuela Andrea Hoffmann, Hans-Georg Buchholz, Helmut J Wieler, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 27, 2025
Comparison of mCRPC [177Lu]Lu-PSMA-617 radioligand therapy with and without concurrent enzalutamide medication in a real-world settingFlorian Rosar, Fadi Khreish, Caroline Burgard, et al.
Cancers|October 26, 2024
Analysis of Molecular Imaging Biomarkers Derived from [18F]FDG PET/CT in mCRPC: Whole-Body Total Lesion Glycolysis (TLG) Predicts Overall Survival in Patients Undergoing [225Ac]Ac-PSMA-617-Augmented [177Lu]Lu-PSMA-617 Radioligand TherapyCaroline Burgard, Fadi Khreish, Lukas Dahlmanns, et al.
Pageof 10